Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Scientific Center for Quality of Healthcare (IQ healthcare), Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
J Antimicrob Chemother. 2018 Jun 1;73(suppl_6):vi30-vi39. doi: 10.1093/jac/dky116.
This study was conducted as part of the Driving Reinvestment in Research and Development and Responsible Antibiotic Use (DRIVE-AB) project and aimed to develop generic quality indicators (QIs) for responsible antibiotic use in the inpatient setting.
A RAND-modified Delphi method was applied. First, QIs were identified by a systematic review. A complementary search was performed on web sites of relevant organizations. Duplicates were removed and disease and patient-specific QIs were combined into generic indicators. The relevance of these QIs was appraised by a multidisciplinary international stakeholder panel through two questionnaires and an in-between consensus meeting.
The systematic review retrieved 70 potential generic QIs. The QIs were appraised by 25 international stakeholders with diverse backgrounds (medical community, public health, patients, antibiotic research and development, regulators, governments). Ultimately, 51 QIs were selected in consensus. QIs with the highest relevance score included: (i) an antibiotic plan should be documented in the medical record at the start of the antibiotic treatment; (ii) the results of bacteriological susceptibility testing should be documented in the medical record; (iii) the local guidelines should correspond to the national guidelines but should be adapted based on local resistance patterns; (iv) an antibiotic stewardship programme should be in place at the healthcare facility; and (v) allergy status should be taken into account when antibiotics are prescribed.
This systematic and stepwise method combining evidence from literature and stakeholder opinion led to multidisciplinary international consensus on generic inpatient QIs that can be used globally to assess the quality of antibiotic use.
本研究是“促进研发投资和负责任使用抗生素(DRIVE-AB)”项目的一部分,旨在制定住院环境中负责任使用抗生素的通用质量指标(QIs)。
采用 RAND 改良 Delphi 法。首先,通过系统评价确定 QIs。在相关组织的网站上进行补充搜索。去除重复项,并将疾病和患者特定的 QIs 合并为通用指标。通过两轮问卷调查和一次中间共识会议,由多学科国际利益相关者小组评估这些 QIs 的相关性。
系统评价检索到 70 个潜在的通用 QIs。25 名具有不同背景(医疗社区、公共卫生、患者、抗生素研发、监管机构、政府)的国际利益相关者对 QIs 进行了评估。最终,有 51 个 QIs 达成共识。相关性得分最高的 QIs 包括:(i)抗生素治疗开始时应在病历中记录抗生素计划;(ii)细菌药敏试验结果应记录在病历中;(iii)当地指南应与国家指南相对应,但应根据当地耐药模式进行调整;(iv)医疗机构应设立抗生素管理计划;(v)开处方时应考虑过敏状态。
本研究采用结合文献证据和利益相关者意见的系统逐步方法,就可用于全球评估抗生素使用质量的通用住院 QIs 达成了多学科国际共识。